By Patricio Ledesma, Founder and CEO, Sofpromed
Table of Contents
Real-World Evidence (RWE) has become one of the most important components of modern clinical research.
Over the last fifteen years, I have seen a significant shift in how pharmaceutical companies, biotech sponsors, medical device developers, and academic investigators generate clinical evidence.
Randomized controlled trials (RCTs) remain the gold standard for demonstrating efficacy and safety, but they cannot answer every question.
Increasingly, healthcare stakeholders want to understand how treatments perform in routine clinical practice, across broader patient populations, and over longer periods of time.
That is where Real-World Evidence studies play a critical role.
At Sofpromed, we have supported sponsors worldwide in the planning, execution, monitoring, and analysis of observational studies, patient registries, retrospective chart reviews, prospective non-interventional studies, and post-authorization safety studies.
These projects often appear simpler than interventional clinical trials, but in reality they require substantial operational expertise, regulatory knowledge, robust data management, and sophisticated statistical methodologies.
In this article, I will explain how a Clinical Research Organization (CRO) supports Real-World Evidence studies from start to finish, including ethics approvals, site contracts, project management, monitoring, data management, statistical analyses, and reporting.
I will also describe how we at Sofpromed support sponsors globally in the successful execution of these studies.
Understanding Real-World Evidence Studies
The U.S. Food and Drug Administration (FDA) defines Real-World Evidence as clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data (RWD).
Table 1. Real-World Data Sources
|
Source |
Examples |
|
Electronic Health Records (EHR) |
Epic, Cerner, Meditech |
|
Disease Registries |
Oncology registries, rare disease registries |
|
Claims Databases |
Insurance claims and reimbursement records |
|
Hospital Databases |
Laboratory results, imaging databases |
|
Pharmacy Records |
Drug dispensing information |
|
Wearables and Digital Health Tools |
Smartwatches, remote monitoring devices |
|
Patient Reported Outcomes |
Quality-of-life surveys |
|
National Health Systems |
Population health databases |
The pharmaceutical industry increasingly relies on RWE to support:
- Regulatory submissions
- Health technology assessments (HTAs)
- Market access activities
- Post-marketing surveillance
- Safety evaluations
- Label expansion strategies
- Rare disease research
- Comparative effectiveness research
The global growth of RWE studies has created a need for CROs that can manage these projects efficiently while ensuring scientific rigor and compliance with local regulations.
Why Sponsors Use CROs for RWE Studies
One of the most common misconceptions is that non-interventional studies are easy to conduct.
In reality, many sponsors underestimate the operational complexity involved.
Consider a multinational observational oncology study involving:
- 150 sites
- 20 countries
- 3,000 patients
- 5 years of follow-up
Even though patients receive standard-of-care treatment, sponsors still need:
- Ethics approvals
- Site contracts
- Data collection tools
- Monitoring oversight
- Quality control processes
- Safety reporting procedures
- Statistical analysis plans
- Clinical study reports
Without experienced operational support, timelines can quickly become delayed.
An experienced CRO provides a structured operational framework that allows sponsors to focus on scientific objectives while the CRO manages execution.
Study Feasibility and Project Planning
Every successful RWE study starts with a comprehensive feasibility assessment.
At Sofpromed, we begin by evaluating:
Patient Availability
We determine:
- Expected patient populations
- Incidence and prevalence rates
- Geographic distribution
- Recruitment capabilities
Data Availability
Not all healthcare systems collect the same information.
We assess:
Table 2. Availability of Data in RWE Studies
|
Data Element |
Availability Assessment |
|
Demographics |
High |
|
Safety Data |
High |
|
Biomarkers |
Variable |
|
Imaging Data |
Variable |
|
Quality of Life Data |
Often Limited |
|
Survival Data |
Generally High |
This early planning prevents costly protocol amendments later.
Country Selection
Different countries have different requirements regarding:
- Data privacy
- Ethics approvals
- Patient consent
- Secondary use of healthcare data
Selecting appropriate countries early significantly improves timelines.
Ethics Committee and Regulatory Approvals
One of the most important CRO responsibilities is obtaining ethics approval.
Many sponsors assume observational studies face minimal regulatory oversight.
This is not true.
Depending on the jurisdiction, approvals may be required from:
- Ethics Committees (ECs)
- Institutional Review Boards (IRBs)
- Data Protection Authorities
- Hospital Research Offices
- National Competent Authorities
Table 3. Ethics Approval Requirements for RWE Studies
|
Region |
Ethics Approval Required |
|
European Union |
Yes |
|
United Kingdom |
Yes |
|
United States |
Usually IRB |
|
Canada |
Research Ethics Board |
|
Australia |
Human Research Ethics Committee |
|
Japan |
Institutional Ethics Committee |
A CRO coordinates submission packages and communication with these authorities.
At Sofpromed, our regulatory specialists prepare:
- Study protocols
- Informed consent forms
- Patient information sheets
- Investigator documentation
- Data privacy documentation
- GDPR compliance packages
Data Privacy and GDPR Compliance
Data privacy has become one of the most critical aspects of RWE studies.
Modern observational projects frequently involve:
- Cross-border data transfer
- Large patient datasets
- Secondary use of health data
Compliance is mandatory.
Table 4. Common Regulations for Data Protection
|
Region |
Regulation |
|
European Union |
GDPR |
|
United Kingdom |
UK GDPR |
|
United States |
HIPAA |
|
Brazil |
LGPD |
|
Canada |
PIPEDA |
|
Singapore |
PDPA |
Failure to comply can jeopardize an entire study.
At Sofpromed, data privacy assessments are integrated into every project from the initial planning stage.
Site Identification and Site Contracting
After approvals are obtained, sites must be activated.
This is often one of the biggest bottlenecks in study startup.
Activities include:
- Site qualification
- Budget negotiation
- Contract negotiation
- Documentation collection
- Investigator training
Large observational studies frequently include:
- Academic hospitals
- Community healthcare networks
- Private clinics
- Disease centers of excellence
Each institution typically requires separate contractual discussions.
Common Contract Elements
- Data ownership
- Publication rights
- Patient compensation
- Data transfer obligations
- Confidentiality requirements
- Study termination rights
At Sofpromed, our clinical operations teams manage site contracting globally, helping sponsors avoid lengthy startup delays.
Investigator Meetings and Site Training
Once sites are activated, training becomes essential.
Although RWE studies are non-interventional, data quality depends heavily on site performance.
Training topics may include:
- Protocol requirements
- Data collection procedures
- Electronic data capture systems
- Safety reporting
- Privacy requirements
- Missing data prevention
We frequently conduct:
- Investigator meetings
- Web-based training
- Site initiation visits
- Refresher training sessions
These investments significantly improve data quality later.
Monitoring in Real-World Evidence Studies
Many people believe monitoring is unnecessary in observational research.
In my experience, that assumption is dangerous.
The monitoring strategy may differ from a Phase III clinical trial, but oversight remains essential.
Objectives of RWE Monitoring
Monitoring helps verify:
- Protocol compliance
- Data completeness
- Data consistency
- Source document availability
- Safety reporting compliance
Risk-Based Monitoring
Modern RWE studies often utilize risk-based approaches.
Table 5. Risk-Based Monitoring Activities in RWE Studies
|
Monitoring Activity |
Typical Frequency |
|
Remote Monitoring |
Monthly |
|
Centralized Monitoring |
Continuous |
|
On-Site Monitoring |
Risk-Based |
|
Data Quality Reviews |
Weekly |
|
Query Reviews |
Ongoing |
This approach reduces costs while maintaining quality.
At Sofpromed, our monitoring teams combine centralized review with targeted site visits based on predefined risk indicators.
Safety Surveillance
Safety oversight remains relevant in many observational studies.
Depending on study objectives, sponsors may need:
- Adverse event collection
- Serious adverse event evaluation
- Pharmacovigilance reporting
- Periodic safety reviews
This becomes particularly important in:
- PASS studies
- Post-marketing commitments
- Long-term follow-up research
Our pharmacovigilance specialists support global safety reporting requirements and maintain compliance with local regulations.
Data Management: The Foundation of Reliable RWE
Data management is often the most underestimated component of Real-World Evidence research.
Poor-quality data produces unreliable evidence.
No statistical methodology can fully compensate for poor underlying data quality.
Data Sources
Modern RWE projects may combine:
- Electronic medical records
- eCRF data
- Registry information
- Laboratory databases
- Wearable device outputs
- Patient-reported outcomes
Managing these diverse datasets requires specialized expertise.
eCRF Design and Database Development
At Sofpromed, our data management team designs study databases that maximize both usability and data quality.
Activities include:
Database Specification
- Variable definition
- Edit check planning
- Validation rules
- User role configuration
eCRF Development
Platforms may include:
- Medidata Rave
- Veeva Vault EDC
- OpenClinica
- REDCap
- Castor EDC
User Acceptance Testing
Before deployment we verify:
- Functionality
- Data validation
- Reporting outputs
- Query behavior
This reduces downstream issues substantially.
Data Cleaning and Quality Management
Large RWE datasets often contain:
- Missing values
- Duplicate records
- Inconsistent measurements
- Coding discrepancies
Systematic data cleaning is therefore essential.
Typical processes include:
Table 6. Data Review Activities in RWE Studies
|
Data Review Activity |
Purpose |
|
Query Management |
Resolve discrepancies |
|
Range Checks |
Identify impossible values |
|
Consistency Checks |
Verify logical relationships |
|
Medical Coding |
Standardize terminology |
|
Duplicate Reviews |
Remove redundant records |
At Sofpromed, dedicated data managers continuously review quality indicators throughout the study lifecycle.
Statistical Analysis
Biometrics represents one of the most critical CRO functions in Real-World Evidence studies.
A common misconception is that RWE analyses are simpler than randomized trials.
In fact, they are often more statistically challenging.
Because treatment assignment is not randomized, multiple sources of bias can affect study outcomes.
Statistical Challenges in RWE
Potential biases include:
- Selection bias
- Confounding
- Information bias
- Missing data bias
- Immortal time bias
- Channeling bias
Addressing these issues requires advanced analytical techniques.
Statistical Analysis Planning
Every study should include a robust Statistical Analysis Plan (SAP).
A high-quality SAP defines:
- Primary endpoints
- Secondary endpoints
- Analysis populations
- Missing data methodologies
- Sensitivity analyses
- Subgroup analyses
At Sofpromed, our statisticians develop SAPs tailored specifically to observational study designs.
Advanced Statistical Methodologies
Common methodologies include:
Propensity Score Methods
Used to reduce treatment allocation bias.
Examples:
- Propensity score matching
- Stratification
- Weighting
- Covariate adjustment
Survival Analysis
Frequently used in oncology and rare disease studies.
Methods include:
- Kaplan-Meier estimation
- Cox proportional hazards models
- Competing risks models
Longitudinal Data Analysis
Useful for long-term follow-up studies.
Examples:
- Mixed-effect models
- Repeated measures analyses
- Generalized estimating equations
Causal Inference Approaches
Increasingly important for regulatory-grade RWE.
Methods may include:
- Inverse probability weighting
- Marginal structural models
- Instrumental variable analyses
Statistical Programming
The complexity of modern RWE requires experienced programmers.
Our statistical programming group typically uses:
Table 7. Statistical Programming Software Types
|
Software |
Typical Application |
|
SAS |
Regulatory analyses |
|
R |
Advanced analytics |
|
Python |
Data processing |
|
SQL |
Database extraction |
|
Power BI |
Dashboard reporting |
Programs are validated according to predefined quality standards.
Study Reporting and Publications
Once data analysis is complete, results must be communicated appropriately.
Deliverables often include:
- Study reports
- Regulatory reports
- Scientific manuscripts
- Congress abstracts
- Health economics publications
A CRO assists with the production of all these outputs.
At Sofpromed, we regularly support publication strategies for sponsors seeking to maximize the scientific value of their data.
How Sofpromed Supports Global RWE Studies
Over the years, we have built a flexible model specifically designed to support Real-World Evidence programs worldwide.
Our services include:
Regulatory Affairs
- Ethics submissions
- Regulatory strategy
- GDPR support
- Privacy assessments
Clinical Operations
- Site identification
- Site activation
- Monitoring
- Project management
Data Management
- Database design
- eCRF development
- Data cleaning
- Medical coding
Biometrics
- Statistical analysis plans
- Statistical programming
- Data analysis
- Reporting
Pharmacovigilance
- Safety oversight
- Case processing
- Signal detection support
A Typical Global RWE Project at Sofpromed
A typical multinational observational study supported by Sofpromed may involve:
Table 8. Characteristics of a Typical RWE Project Managed by Sofpromed
|
Project Component |
Typical Scope |
|
Countries |
10–30 |
|
Sites |
50–300 |
|
Patients |
500–10,000+ |
|
Follow-up Duration |
1–10 Years |
|
Database Records |
Millions |
|
Safety Reports |
Hundreds |
To manage such programs effectively, our teams coordinate activities across regulatory, clinical, data management, biometrics, and pharmacovigilance functions.
This integrated model helps sponsors maintain consistency and quality across all participating countries.
Why Sponsors Choose CRO Support for RWE Studies
From my perspective, the biggest advantage a CRO brings to an RWE study is operational expertise.
Sponsors may conduct only a handful of observational programs each year.
CROs manage dozens simultaneously and develop specialized processes that reduce risk, improve efficiency, and accelerate timelines.
The right CRO can help sponsors:
- Launch studies faster
- Improve data quality
- Reduce protocol deviations
- Maintain regulatory compliance
- Generate publishable evidence
- Support market access objectives
- Prepare regulatory-grade analyses
These benefits become increasingly important as regulatory agencies and payers place greater emphasis on Real-World Evidence.
Final Remarks
Real-World Evidence studies have evolved from secondary research projects into strategic evidence-generation programs that influence regulatory decisions, reimbursement negotiations, clinical guidelines, and patient care.
Although they may appear less complex than traditional clinical trials, successful RWE studies require substantial expertise in ethics approvals, site contracting, project management, monitoring, data management, statistical analysis, and reporting.
In my experience, the greatest risk in Real-World Evidence research is not lack of data.
Today, healthcare systems generate enormous volumes of information.
The real challenge is transforming that information into credible scientific evidence.
That transformation requires the right methodology, the right operational infrastructure, and the right biometrics expertise.
At Sofpromed, we support pharmaceutical companies, biotech organizations, medical device developers, and academic investigators worldwide by providing comprehensive Real-World Evidence services, from protocol development and ethics submissions through data management, statistical analysis, and final reporting.
Our objective is simple: to help sponsors generate reliable evidence that ultimately improves patient care and supports better healthcare decisions around the world.














